Thu, April 19, 2012
Wed, April 18, 2012
Tue, April 17, 2012
Mon, April 16, 2012
Sun, April 15, 2012
Sat, April 14, 2012
Fri, April 13, 2012
Thu, April 12, 2012
Wed, April 11, 2012
Tue, April 10, 2012
Mon, April 9, 2012
Fri, April 6, 2012
Thu, April 5, 2012
[ Thu, Apr 05th 2012 ]: Market Wire
April 30, 2012
Wed, April 4, 2012
Tue, April 3, 2012

First Quarter 2012 Results Date Notification - April 26, 2012


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. 012-results-date-notification-april-26-2012.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012 -- DUBLIN, April 12, 2012 /PRNewswire/ --

Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012

[ ]

DUBLIN, April 12, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: [ SHPGY ]), the global specialty biopharmaceutical company, will announce first quarter 2012 earnings on Thursday April 26, 2012.

 Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT 


Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows:

 UK dial in: 0800-077-8492 or 0844-335-0351 US dial in: 1-866-8048688 or 1-718-3541175 International dial in: +44-844-335-0351 Global Access Numbers: http://www.btconferencing.com/globalaccess/?bid=54_attended Password/Conf ID: 338 270 Live Webcast: http://www.shire.com/shireplc/en/investors 


Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year.  Details can be found on our Investor Relations website [ http://www.shire.com/shireplc/en/investors ].

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: [ http://www.shire.com ].

For further information please contact:

 Investor Relations Souheil Salah (ssalah@shire.com) +44-1256-894-160 Erin K. Kelly (erikelly@shire.com) +1-781-482-9541 


SOURCE Shire plc

[ Back to top ]


Publication Contributing Sources